Do you think privatisation has negatively impact our research capabilities - especially looking at AMR and antibiotic development and its effect on metabolism and insulin levels

The Privatization Challenge in Antibiotic Development

I've spent decades examining how systemic shifts influence our ability to maintain healthy metabolism. Privatization of pharmaceutical research has indeed created significant barriers, particularly in the realm of antimicrobial resistance (AMR) and new antibiotic development. Large corporations prioritize blockbuster drugs with high profit margins, such as those for chronic conditions, over antibiotics that are used short-term and face rapid resistance development. This has led to a 30-year innovation gap where only a handful of new antibiotic classes reached the market since the 1980s.

According to data from the World Health Organization, we lose approximately 1.27 million lives annually to AMR-related infections. The economic model simply doesn't support the $1-2 billion investment needed to bring a new antibiotic to market when usage must be restricted to preserve efficacy. This directly affects patients managing diabetes, blood pressure, and weight struggles in their 40s and 50s, as repeated antibiotic exposure disrupts the gut microbiome, which plays a central role in regulating insulin levels.

How Antibiotics Influence Metabolism and Insulin

In my book and methodology at CFP Weight Loss, we emphasize the gut-metabolism connection. Early-life or frequent antibiotic use can reduce microbial diversity by up to 25%, leading to impaired short-chain fatty acid production. These compounds are essential for improving insulin sensitivity and reducing inflammation that drives joint pain and hormonal weight gain. Studies show that individuals with higher lifetime antibiotic exposure have a 15-20% increased risk of developing type 2 diabetes.

For those embarrassed by past diet failures or overwhelmed by conflicting advice, this science explains why standard calorie-restriction plans often fail after antibiotic courses. The resulting dysbiosis promotes energy harvest from food, making middle-age weight loss feel impossible despite your best efforts. Our approach focuses on rebuilding microbiome resilience through targeted fiber intake (aim for 35g daily from diverse plant sources) and strategic movement that respects joint limitations—no gym marathons required.

Practical Strategies Within Our CFP Framework

Rather than waiting for policy changes to fix privatization's research gaps, we empower individuals with actionable tools. Begin with a 7-day microbiome reset: eliminate ultra-processed foods that feed resistant bacteria while incorporating fermented foods and prebiotic fibers like inulin from onions and garlic. Track your blood glucose response to meals using affordable monitors to understand personal insulin responses.

Incorporate low-impact movement, such as 20-minute daily walks or chair yoga, which research shows can improve insulin sensitivity by 15% within weeks without exacerbating joint pain. Our middle-income clients succeed by focusing on sustainable changes covered partially by insurance wellness visits rather than expensive programs. We address hormonal shifts in perimenopause by prioritizing sleep optimization and stress reduction, which support metabolic recovery post-antibiotic exposure.

Advocating for Balanced Solutions

While privatization has slowed AMR innovation, public-private partnerships like the GARDP offer hope. As individuals, we mitigate effects through informed choices. The CFP Weight Loss method integrates this knowledge so you no longer feel overwhelmed. By understanding these connections between antibiotics, metabolism, and insulin, you can break the cycle of failed diets and achieve lasting results despite systemic challenges.